with potential advantages over the more commonly used antifolate, methotrexate (MTX); however, its use has been limited by severe myelosuppression. Retroviral vectors containing mutant dihydrofolate reductase (DHFR) genes have been used to protect bone marrow cells from MTX, suggesting a similar approach could be used for TMTX. We first screened six variants of human DHFR to determine which allowed maximal TMTX resistance in fibroblasts. A variant enzyme containing a Leu-to-Tyr mutation in the 22nd codon iL22Y) was best, allowing a 100-fold increase in resistance over controls. Murine hematopoietic progenitor cells transduced with an NTIFOLATE DRUGS such as methotrexate (MTX) exert their antiproliferative effect through competitive inhibition of the cellular enzyme dihydrofolate reductase (DHFR), which is essential for de novo synthesis of thymidylate and purine nucleotides.' MTX is the most frequently used drug in this class, but its clinical usefulness is limited both by the emergence of drug-resistant tumor cells and by toxicity to normal host tissues. Trimetrexate (TMTX) is a newer antifolate that offers attractive properties for clinical use. Because TMTX can passively enter cells that have become resistant to MTX through alterations in the folate active transport mechanism,2 TMTX is active against certain MTXresistant tumors.' In phase I and I1 clinical trials, TMTX has shown activity in some advanced pediatric and adult tumors, but its use was often limited by severe myelosuppres~i o n .~" In most cases, neutropenia and thrombocytopenia were the dose-limiting toxicities, suggesting that treatments which lessen hematopoietic suppression may increase the clinical usefulness of TMTX. Antifofate-induced toxicity in normal tissues can be ameliorated by administering 5-formyltetrahydrofolate (leucovorin), which bypasses the DHFR block by providing reduced folate. Despite the common use of high-dose MTX with leucovorin rescue, animal models and clinical trials have shown that leucovorin administration can also rescue tumor so that the value of this approach for increasing the therapeutic index of antifolate drugs has been questioned.'".''
NTIFOLATE DRUGS such as methotrexate (MTX) exert their antiproliferative effect through competitive inhibition of the cellular enzyme dihydrofolate reductase (DHFR), which is essential for de novo synthesis of thymidylate and purine nucleotides.' MTX is the most frequently used drug in this class, but its clinical usefulness is limited both by the emergence of drug-resistant tumor cells and by toxicity to normal host tissues. Trimetrexate (TMTX) is a newer antifolate that offers attractive properties for clinical use. Because TMTX can passively enter cells that have become resistant to MTX through alterations in the folate active transport mechanism,2 TMTX is active against certain MTXresistant tumors.' In phase I and I1 clinical trials, TMTX has shown activity in some advanced pediatric and adult tumors, but its use was often limited by severe myelosuppres~i o n .~" In most cases, neutropenia and thrombocytopenia were the dose-limiting toxicities, suggesting that treatments which lessen hematopoietic suppression may increase the clinical usefulness of TMTX. Antifofate-induced toxicity in normal tissues can be ameliorated by administering 5-formyltetrahydrofolate (leucovorin), which bypasses the DHFR block by providing reduced folate. Despite the common use of high-dose MTX with leucovorin rescue, animal models and clinical trials have shown that leucovorin administration can also rescue tumor so that the value of this approach for increasing the therapeutic index of antifolate drugs has been questioned.'".' ' Another approach for increasing the therapeutic index of TMTX would be to transfer antifolate-resistant DHFR genes to bone marrow cells, thereby providing TMTX-resistant DHFR activity to hematopoietic cells. A number of investigators have transferred antifolate-resistant DHFR genes to murine bone marrow cells as a strategy to diminish MTXinduced myelosuppression in transplanted mice.I2-l5 Although DHFR gene transfer was associated with increased survival after MTX treatment, it was not clear whether this was due to protection of hematopoiesis. In the studies where blood counts were reported, relatively low doses of MTX were given immediately after myeloablative irradiation and transplant. Because this design would be expected to result in overlapping toxicity from irradiation and drug treatment, the degree of drug-induced myelosuppression could not easily be determined. Furthermore, only hematocrits and total white blood cell counts were reported for peripheral blood count data. Because these numbers are influenced by variables other than marrow production rates, such as hydration status and lymphocyte counts, they may not accurately reflect the degree of myelosuppression.
After identification of a mutant DHFR gene encoding a single amino acid substitution leading to MTX resistance,I6 a number of other human and rodent DHFR variants have been identified that also confer antifolate re~istance."~~' Surprisingly, there is little information comparing these variants for their ability to confer antifolate resistance in cells. Substantial biochemical data have shown that human DHFR variants with particular substitutions in the 22nd and 31st codons have greatly reduced binding affinities for antifolate drugs yet retain considerable catalytic activity,'*-" suggesting that these genes may be ideally suited for use in gene therapy vectors. Based on these prior studies, we directly compared a series of human DHFR cDNAs encoding various substitutions at codons 22 and 31 for their ability to confer cellular resistance to TMTX. A cDNA encoding a leucineto-tyrosine substitution at the 22nd codon (L22Y) gave the highest levels of TMTX resistance in both murine fibroblasts and hematopoietic progenitor cells. When mice were transplanted with cells transduced with a retroviral vector containing the L22Y cDNA, attenuation of myelosuppression . .. was seen that was proportional to the proviral copy number within individual animals. These experiments define an optimized system for making bone marrow cells resistant to TMTX. which could ultimately be used to increase the effectiveness of TMTX in cancer therapy.
Ha-LTR

HFH
MATERIALS AND METHODS
Materials. Restriction enzymes, glutamine, penicillin, and streptomycin were purchased from GlBCO BRL, Gaithersburg, MD. Dialyzed fetal bovine serum ( l , O O O molecular weight cutoff), thymidine phosphorylase, and MTX were from Sigma, St Louis, MO. Fetal bovine serum was from Biofluids Inc. Rockville, MD. Methylcellulose culture media (Methocult 3430) was from Stem Cell Technologies, Vancouver, Canada. Phosphate-buffered saline (PBS) and Dulbecco's modified Eagle's medium (DMEM) were from BioWittaker, Walkersville, MD. Murine interleukin-3 (IL-3) and human interleukin-6 (IL-6) were from Pepro Tech, Inc. Rocky Hill, NJ. TMTX was a gift from the National Cancer Institute (NCI; Bethesda, MD). RNAzol B was from Tel-Test, Inc. Friendswood, TX. All other materials were as previously described.".".'5 DNA manipulations. Construction and expression of mutant cDNAs for human DHFR (hDHFR) have been described previously.2'." Construction of retroviral vectors was performed by replacing the Xho I-Hind111 fragment of pSP72 (Promega, Madison, WI) with the Xho I-Hind111 fragment of the variant cDNAs from the pDS5hDHFR expression vectors. A BamHI site was introduced into this construct 5' to the polyadenylation signal by polymerase chain reaction (PCR) amplification. The BamHl (Klenow blunted)-EcoRI fragment was cloned into the HinclI-EcoRI sites of Bluescript I1 KS+ (Strategene, La Jolla, CA). The Sac 11-Xho I fragment from these bluescript constructs were used to replace the Sac 11-Xho I fragment containing the multiple drug resistance gene in a Harvey murine sarcoma virus-based retroviral vector Ha-MDR." The thymidine kinase (TK) promoter and NeoR genes were introduced by digesting pGlmtNEO (a gift from Genetic Therapies Inc. Gaithersburg, MD) with Cla I (Klenow blunted) and Xho I and cloning this fragment into the Xho I-Stu I sites of the retroviral vector (Fig 1 ) .
TMTX-glucuronate synthesis and kinetic parameters. TMTX was received as the base from the Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, NCI. It was converted to the glucuronate by suspension of the base ( 1.163 g; 3.15 mmol) in 100 mL of water and vigorous stimng while a solution of D-glucuronic acid (0.61 I g; 3.15 mmol) in 25 mL of water was added dropwise. When all the solid had dissolved, the solution was freeze-dried to give 1.55 g of the glucuronate (yield, 87%). Steady-state kinetic constants and inhibitor affinities were determined as previously d e~c r i b e d . '~.~'~~~~~~ Cell culture and retrovirus packaging. Plasmids containing retroviral vectors were introduced into the murine fibroblast amphotropic packaging cell line PA3172X using a commercially available kit for calcium phosphate transfection (Specialty Media, Inc. Lavallette, NJ). After 48 hours, cells were selected with 0.75 mg/mL active G418 for 10 days. Selected cells were cultured in DMEM containing 10% fetal bovine serum, 4 mmol/L glutamine, 1 0 0 U/ mL penicillin, and 1 0 0 & n L streptomycin. After selection in G41 8, 1 X 1 0 ' transduced cells were plated in media containing either MTX or TMTX. and viable colonies were scored after 10 days. Dialyzed fetal bovine serum was used during antifolate selection to minimize thymidine rescue.
For the generation of ecotropic producer clones, retroviral vectors lacking the TK promoter and the NeoR genes were used (Fig I) . Viral-containing supernatants from transiently transfected PA3 17 cell populations were used to infect the ecotropic viral packaging cell line GP + E86.Z9 Ecotropic producer clones were isolated by selection with 500 nmol/L TMTX for 10 days.
Southern and Norfhern analvsis. DNA was isolated by trypsinizing a near-confluent 100-mm culture dish, pelleting the suspended cells by centrifugation, and incubating I X IO" cells for 17 hours at 37°C in 1 0 0 mmol/L NaCI, 10 mmol/L EDTA, 50 mmol/L Tris pH 8.0, 1 % sodium dodecyl sulfate (SDS), and 0.6 mg/mL proteinase K. The DNA was extracted with phenol and chloroform, precipitated in ethanol, and resuspended in 10 mmol/L Tris, I mmol/L EDTA, pH 8.0. The concentration of DNA was determined spectrophotometrically, and 10 pg was digested for 17 hours with Nhe I, separated on a I% agarose gel, transferred to a nylon membrane, and probed with the full-length wild-type hDHFR cDNA (Fig l) . RNA was isolated according to the manufacturer's recommendations by adding RNAzol B directly to a near-confluent 100-mm culture dish. RNA was separated, transferred to a nylon membrane, and probed with the full-length wild-type hDHFR cDNA.
Bone marrow transduction, transplantation. and TMTX administration. Donor mice (C57B1/6J) were injected 48 hours before marrow harvest with 150 mgkg of 5-fluorouracil, and then bone marrow cells were collected and prestimulated with 20 ng/mL of murine IL-3 and 50 ng/mL of human IL-6 for 48 hours."'.'' Cells were then harvested and placed in coculture with ecotropic producer cells in the presence of IL-3, L-6, and polybrene, as previously described.3" After 48 hours of coculture, 2 X IO" nucleated bone marrow cells were injected via the tail vein into WB/B6FI W W recipients. Reconstitution with donor-derived cells was determined by celluloseacetate electrophoresis at 12 weeks after transplant. Reconstituted mice received TMTX by intraperitoneal injections given once daily for 5 consecutive days. Mice that received TMTX 1 0 0 mgkgld were rechallenged with the same dose schedule 32 days after the first dosing. Blood samples for the determination of hematocrit, reticulocyte index, white blood cell count, and absolute neutrophil counts were collected in heparinized microcapillary tubes from the retroorbital venous plexus 24 hours before TMTX administration and 24 hours after administration of the last TMTX dose. White blood cell counts were determined by counting nucleated cells in 2% acetic acid on a hemacytometer. White blood cell count differentials were performed by manual scoring of Wright-stained blood smears. Methylene blue-stained blood smears were used to calculate the proportion of red cells that were reticulocytes. The reticulocyte index was calculated by multiplying the hematocrit with the percent reticuloFor personal use only. on November 16, 2017. by guest www.bloodjournal.org From cytes, and the absolute neutrophil count by multiplying the total white blood cell count by the proportion of granulocytes on the differential.
For progenitor assays, transduced bone marrow cells were plated at 0.75 X 105/mL in 3430 methylcellulose media (Stem Cell Technologies) containing various concentrations of MTX or TMTX. The methylcellulose was pretreated with thymidine phosphorylase (1 U/ mL serum) for 16 hours at 37°C to reduce thymidine rescue. Total colonies derived from clonogenic progenitors were scored after IO days.
Analysis of peripheral Mood DNA. DNA was isolated from peripheral blood nucleated cells obtained from the retroorbital venous plexus as previously de~cribed.~' PCRs were performed according to the manufacturer's protocol (Perkin Elmer, Nonvalk, CT), except that 0.2 pL of P3'-labeled deoxycytidine triphosphate (dCTP; 800 pCilmmollL) was added to each reaction. Primers for the PCR amplification of the beta-globin sequence have previously been reported.32 For the amplification of the Ha-L22Y sequence, primers were as follows: left-hand primer, 5'-CAGGTGTTCTCTCTGATGTC-3'; right-hand primer, 5'-TGAAGTCAACAGTCAGGAGC"', the locations of which are depicted in Fig I. Amplification of the Ha-L22Y sequence was performed on 300 ng DNA for 27 cycles of 1.5 minutes at 94°C. 1 minute at 56"C, 1.5 minutes at 72"C, and then one cycle of 72°C for 8 minutes. Amplification parameters for the beta-globin sequence were identical, except that 22 cycles were used. After amplification, equal volumes from each reaction were mixed and separated on a 5% nondenaturing polyacrylamide gel.
PCR analysis of bone marrow DNA and RNA. Mice were killed by cervical dislocation, and bone marrow cells were harvested from the hind limbs. Total RNA was isolated using RNAzol B according to the manufacturer's recommendations. DNA was isolated as previously described" and amplified as described above. RNA (200 ng) was reverse-transcribed using random hexamers as primers for reverse transcription and was PCR-amplified using primers specific for a portion of the beta-actin gene sequence3' or the Ha-L22Y sequence.
RESULTS
Generation of retroviral vectors containing variant hDHFR cDNAs. Six DHFR cDNAs were chosen for testing, based on extensive prior work22923 showing that some of these variants possessed favorable kinetic properties for use in protecting cells from antifolate drugs (Table 1) . For example, the L22R substitution results in a dramatic decrease in antifolate binding affinity but also reduces the catalytic efficiency of the enzyme by greater than 4 orders of magnitude relative to the wild-type enzyme. In contrast, the F31S variant has relatively well-preserved catalytic efficiency but is much more sensitive to antifolate inhibition in vitro. The L22Y mutation would appear to have ideal kinetic properties for conferring drug resistance, because the catalytic efficiency of the enzyme is relatively well preserved despite a large reduction in the affinity for antifolate drugs.
For transduction of bone marrow cells, these DHFR cDNAs were inserted under control of the viral promoter in the Harvey murine sarcoma virus (HaMSV) vector (Fig 1B) . The HaMSV was chosen based on prior demonstration that this vector directs long-term expression in primitive hematopoietic cells from transplanted mice.33 An analogous vector, which also contained a downstream NeoR transcription unit, was used for transfection of cultured PA317 cells (Fig 1A) .
ldentijcation of the DHFR variant best suited for generat- ing TMTX resistance. Plasmid DNA constructs containing the NeoR gene were transfected into PA3 17 murine fibroblast packaging cells. After G418 selection, polyclonal populations of transfected PA317 cells were cultured in various concentrations of MTX and TMTX, and the numbers of resistant colonies were compared with those on plates containing no drug. The L22Y and F3 1G vectors consistently gave the best resistance to both MTX and TMTX (Fig 2) . Resistance to TMTX achieved with the L22Y, F3 lG, F31S, and L22R vectors was much higher than resistance to MTX. In these cases, the concentration of TMTX that killed 50% of cells (ICso) was about 1 log greater than that for MTX ( Table 2 ). The highest levels of resistance to both MTX and TMTX were obtained with the L22Y construct, with a 9.2-fold increase in ICso for MTX and a 100-fold increase in ICso for TMTX.
To show that differences in antifolate resistance were due to intrinsic enzyme properties rather than differences in vector copy number or expression, Southern and Northern analyses were performed using populations of transfected cells grown with and without MTX. Northern analysis was used to measure levels of vector-derived mRNA in cells containing the L22R, F31G, and L22Y variants (Fig 3B and C) . In cells grown in 200 nm MTX, mRNA levels were, in fact, lowest with the L22Y vector. Similarly, Southern analysis of genomic DNA showed that the L22Y vector copy number, at any given MTX concentration, was lower than that seen with the other variants (Fig 3A) . These results show that the increased drug resistance seen with the L22Y vector was not due to increases in vector expression or copy number relative to less active vectors. For all vectors tested, MTX treatment of the polyclonal population resulted in increases in copy number and mRNA levels. These increases presumably reflect selection and expansion of clones, initially present within the polyclonal population, which express large amounts of DHFR message due to relatively high proviral copy numbers. It is also possible that amplification of vector
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eage-committed progenitors was 100% with both producer clones and that differences in colony survival were not due to relative differences in transduction efficiency between the two producer clones. Recent analogous experiments have shown that an amphotropic L22Y vector conferred similar levels of TMTX resistance to human bone marrow-derived progenitor cells, although the transduction efficiency of human progenitors was substantially lower (data not shown).
Long-term persistence and expression o j the DHFR \ Wtors in transplanted mice. To determine whether the F3 1 G and L22Y vectors could be transferred to long-term repopulating cells and to examine if these vectors would be stably expressed in vivo, several mice were analyzed for gene transfer and expression. Bone marrow was harvested from an F31G and an MDRl animal 30 weeks after transplant, and from an L22Y animal 26 weeks after transplant. Semiquantitative PCR analysis" showed both DHFX animals had proviral DNA sequences in bone marrow cells (Fig 5) , indicating that progeny of gene-modified stem cells were present in the bone marrow. The vector copy number was significantly higher in the L22Y animal, which likely reflects a higher proportion of vector-modified cells in the bone marrow from this animal.
Semiquantitative RNA analysis by PCR" showed that vector sequences were expressed in both animals, but that overall mRNA levels were much higher in the L22Y animal, presumably due to the higher vector copy number within the bone marrow population. Bone marrow cells were also assayed for TMTX-resistant progenitor cells in semisolid culture. Approximately 20% of the bone marrow progenitors within the L22Y marrow were TMTX-resistant, and PCR analysis of colonies grown in the absence of drug showed that 2 of 11 colonies contained L22Y DNA sequences (data not shown). Collectively, these data suggest that approximately 20% of the stem cell progeny contained and expressed the transferred L22Y gene 26 weeks after transplant. In contrast, little resistance was seen with the F3 1 G marrow, most likely due to the small number of vectorexpressing cells within the bone marrow. Protection of bone marrow progenitor cells. Vectors containing the F3 l G and L22Y cDNAs, but lacking the NeoR gene, were used to generate ecotropic producer clones. The two clones used for bone marrow experiments were shown to contain unrearranged provirus by Southern analysis and to have equivalent titers of approximately 5 X 10' infectious particles per milliliter. To determine whether vector transfer resulted in drug-resistant clonogenic progenitor cells, transduced marrow was directly plated in semisolid media containing various concentrations of MTX or TMTX, and erythroid and myeloid colonies were scored after 10 days. Cells transduced with a vector containing the MDRl gene in place of the DHFR cDNA were used as controls. Both DHFR cDNAs provided significant protection against MTX (Fig 4) , with IC5,, values increased about 30-fold over control cells. The L22Y variant gave the best TMTX resistance, conferring a 100-fold increase in the G o . For both the F3 1G and L22Y vectors, PCR analysis showed that all colonies on the drugfree plates contained vector DNA sequences (data not shown), indicating that the transduction efficiency of lin- [Antifolate] (nM) Severe neutropenia was noted in all control animals at 6 days after beginning drug treatment, with absolute neutrophil counts below 500 pL in all cases (Fig 6B) . Similarly, reticulocyte production was completely absent in three of four controls, with very low numbers of reticulocytes in the fourth animal (Fig 6C) . In contrast, 6 of IO L22Y animals were protected from neutrophil count nadirs less than 500/pL, and 7 of IO had preserved reticulocytosis. Animals were allowed to recover and were rechallenged with TMTX 32 days after the first treatment course. Again, controls showed severe neutropenia and reticulocytopenia, while consistent protection was noted in the subset of L22Y animals that were resistant to the first treatment course. After recovery from the first hematopoietic nadir, DNA was prepared from peripheral blood leukocytes and assayed by PCR to determine the average copy number of the L22Y provirus (Fig 6A) . The DHFR DNA copy number, presumably reflecting the fraction of gene-modified hematopoietic cells within individual mice, was highly correlated with the degree of protection from drug toxicity. The seven mice with the highest copy numbers showed consistent protection of erythropoiesis and granulopoiesis. In contrast, animals IO, 4, and 9 had low to undetectable levels of vector sequences, explaining their lack of protection against myelosuppression. These data show a strong correlation between the L22Y gene dose and the degree of hematopoietic protection against TMTX toxicity.
To determine whether the L22Y vector would protect at a higher dose of TMTX, a second group of L22Y and MDRl control mice were treated with 130 mgkg of TMTX daily for S days (Fig 7) . All mice were treated 26 to 30 weeks after transplant. Three of the six MDR control mice died on days 4, S, and 7, respectively, after initiation of treatment, and three of five L22Y mice died, two at 7 days and one at 8 days after starting treatment. Surviving control animals showed near complete absence of both neutrophils and reticulocytes 6 days after starting TMTX treatment (Fig 7A and  B) . Protection from myelosuppression was again noted in L22Y mice with high vector copy numbers (Fig 7C) . Animals M14 and MIS had no decrease in neutrophil count, only modest decreases in the reticulocyte index, and relatively high L22Y copy numbers and were long-term survivors. In contrast, animals M 12 and M I6 had very low L22Y copy numbers, developed severe neutropenia, and died shortly after treatment. Mouse MI3 died on day 7 despite a relatively high L22Y copy number. On the day before death, this mouse had a hematocrit of IS% with preserved reticulocytosis, indicating death was probably due to gastrointestinal bleeding. MDRl control mouse M4 had a neutrophil count (ANC) of 34/pL and a platelet count of 98,00O/pL on the day of death. Necropsy results showed fresh blood throughout the gut lumen and moderately severe ileal mucosal atrophy. Collectively, these findings suggest that death most probably resulted from gastrointcstinal bleeding or neutropenic sepsis. Autopsy data from the L22Y mouse M 12 showed no gastrointestinal bleeding but moderately severe ileal mucosal atrophy and a premorbid ANC of S6/pL. all of which suggest death from neutropenic sepsis.
DISCUSSION
Before developing procedures for clinical use of mutant DHFR cDNAs. it seems appropriate to identify the most suitable variant of human DHFR with which to protect cells. Hematologic nadirs and vector copy numbers in transplanted mice receiving l00 mglkgld TMTX for 5 days. At 18 weeks after transplant, L22Y mice (mice 1 through 11) and controls containing the MDRl gene (mice l 2 through 15) were treated with TMTX for 5 days. On day 6, the absolute neutrophil count (B, U) and the reticulocyte index (C, 0) were determined. After recovery, DNA was prepared from peripheral blood leukocytes (day 25) and assayed by semiquantitative PCR for the concentration of DHFR-vector sequences or beta-globin sequences (A). The mice were then rechallenged with the same dose of TMTX 32 days after starting the first treatment, and hematologic nadirs were again determined on day 6 of the second treatment cycle IB and C, m). Mice human DHFR. which we had previously identified to be resistant to antifolate binding in vitro."." for their ability to confer cellular resistance to TMTX. As predicted. the L22Y variant was the best for conferring TMTX resistance to both murine fibroblasts and hematopoietic progenitor cells grown in vitro. These experiments give some indication of how kinetic parameters correlate with levels of cellular resistance. If the TMTX binding affinity was the only important parameter, the L22R variant would be predicted to give the highest level of TMTX resistance. This was not the case, presumably due to the greatly reduced catalytic efficiency of L22R. The L22Y substitution is apparently the best compromise between reduced antifolate binding and preservation of catalytic efficiency. Although the L22Y variant was not formally proven to be superior to the other vectors by a direct in vivo comparison. the in vitro data strongly suggest that the L22Y variant may be the optimal DHFR cDNA for protecting against antifolate-induced myelosuppression.
Certain variants gave much higher levels of resistance to TMTX than to MTX. In PA3 17 cells transfected with the L22Y. F3 IG, F31S. and L22R vectors, the IC,,, for TMTX was about 1 log greater than for MTX. This increase in resistance is best explained by the greater specificity of TMTX for DHFR inhibition compared with MTX. After entry into the cell. MTX forms polyglutamates that can inhibit thymidylate synthase and enzymes at one or more steps in the de novo purine nucleotide biosynthetic pathway. When cells expressing variant DHFR are exposed to increasing MTX concentrations, intracellular levels of MTX polyglutamates become high enough to kill cells through these other pathways. In contrast, TMTX cannot form polyglutamates and kills cells predominantly through DHFR inhibition. In cells expressing antifolate-resistant DHFR variants. the limiting factor for survival in TMTX is the degree of drugresistant DHFR activity, rather than the onset of DHFRindependent killing seen with MTX. Some mutant cDNAs such as L22F and F31 W did not confer increased cellular resistance to TMTX compared with MTX. This is likely due to the relatively high antifolate affinities associated with both variants (Table l ) , which result in killing at relatively low TMTX concentrations.
From previous studies using transplanted mice,''-'5 the influence of DHFR gene transfer on MTX-induced myelosuppression is difficult to interpret for a number of reasons. In the studies that comment on peripheral blood counts, only hematocrits and total white blood cell counts are reported. Neutrophil and reticulocyte counts are better indicators of marrow production, because these cells have a relatively short half-life in the peripheral circulation. In most of these prior studies, relatively low doses of MTX were given immediately after irradiation and transplant. Our study differs in that animals were allowed to completely reconstitute with For personal use only. on November 16, 2017. by guest www.bloodjournal.org From gene-modified cells before being challenged with drug. This design not only allows uncomplicated analysis of hematologic parameters, but is analogous to posttransplant chemotherapy proposed for use in human gene therapy trial^.'^.'^ Some L22Y mice were well protected from TMTX, while others were not. Vector copy number in peripheral blood leukocytes strongly correlated with the degree of myeloprotection seen in individual mice. This relationship between gene dose and the degree of protection underscores the importance of optimizing transduction of human cells if this approach is to be successful clinically. Despite recent advances, human stem cell transduction efficiencies may be inadequate to allow drug-resistant hematopoiesis after reconstitution from autologous tran~plantation.~~.~~ In vitro selection with MTX has been used to enrich for drug-resistant human hematopoietic cells that contain a DHFR vector3' and may be useful in circumventing low transduction efficiencies. TMTX should offer significant advantages for in vitro selection, given the substantially increased resistance in L22Y-expressing cells that TMTX offers over MTX. It may also be possible to select TMTX resistant cells in vivo after transplant, as has been performed with taxol and MDRI vector^.'*^^^ Another strategy to achieve high proportions of transduced cells in transplant recipients would be to repetitively administer drug-resistant progenitor cells in unablated recipients receiving standard doses of chemotherapy. The feasibility of this approach has recently been established using a methylguanine methyltransferase gene to protect from nitrosourea toxicity!'
The ultimate usefulness of this approach for cancer therapy will require testing in appropriate clinical trials. An important remaining question is whether dose escalation can be achieved by transfer of the L22Y vector to bone marrow cells. Superficially, the lack of a survival advantage in the L22Y group treated with the higher TMTX dose would seem to indicate that the L22Y vector did not enable dose intensification. It may be seen that such a conclusion is unwarranted, however, when it is considered that two of the three L22Y animals that died had very low levels of gene transfer. Even if high-level gene transfer could be achieved in most cases, dose escalation could be limited by gastrointestinal toxicity. Clinical trials have shown that although the doselimiting toxicity of TMTX was marrow suppression, moderately severe mucositis was also It has recently been reported that mice transplanted with transgenic marrow expressing drug-resistant DHFR transgenes were protected not only from MTX-induced myelosuppression, but also from gut necrosis. These results show that gene transfer-mediated preservation of hematopoiesis can result in secondary protection from antifolate-induced gastrointestinal Even if mucositis would prevent significant dose escalation in patients, elimination of myelosuppression would likely be of clinical benefit.
